US Tardive Dyskinesia Market Size, 2016 Trends and 2025 Forecasts Now Available at

Wednesday, November 30, 2016 Research News
Email Print This Page Comment bookmark
Font : A-A+ adds "US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)" report to its research store.

PUNE, India, Nov. 29, 2016 /PRNewswire-iReach/ -- The report entitled "US Tardive Dyskinesia Market: Size, Trends &

Forecasts (2016-2025)", provides analysis of the US tardive dyskinesia market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the major drugs (both existing and in pipeline) analysis, by penetrations, by revenue, etc.

Photo -

Complete report available at

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US tardive dyskinesia market has been forecasted for the years 2016-2025, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.

Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries are some of the key companies in the US tardive dyskinesia market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.

Company Coverage

  • Valeant Pharmaceuticals (Tertrabenazine)
  • Neurocrine Biosciences (Valbenazine)
  • Teva Pharmaceutical Industries (SD-809)

Psychosis is a condition described as loss of contact with reality. And the people suffering from this condition are called psychotics. Some of the signs and symptom of psychosis are: difficulty in concentrating, depressed mood, sleeping too much or not enough, anxiety, etc. The two main types of psychiatric disorder related to tardive dyskinesia are Schizophrenia and Bipolar Disorder.

Involuntary movements of face, lips, tongue, extremities and trunk, is called tardive dyskinesia. This disease is caused by regular and long term intake of dopaminergic antagonist medications/ antipsychotics as a prescription for schizophrenia and bipolar disorder. Some of the signs and symptoms of tardive dyskinesia are grimacing, tongue movements, lip smacking, lip puckering, pursing of the lips, excessive eye blinking, etc.

Purchase a copy of this report at

Tardive dyskinesia has many different treatments, including vitamin E, benzodiazepines, levodopa, reserpine, botullinum toxin, tetrabenazine, dopamine-depleting agents, and calcium channel blockers. Along with these, two new treatments are in the pipeline: Valbenazine and SD-809.

The US tardive dyskinesia market is expected to increase at a significant growth rate during the forecasted period (2016-2025). The US tardive dyskinesia market is supported by various growth drivers, such as increase in number of schizophrenia patients, rising bipolar disorder patients, etc. Yet, the market faces certain challenges, such as, increased use of atypical antipsychotics, under-diagnosed market, side effects of drugs, etc.

Major Points from Table of Contents:

1. Executive Summary2. Introduction2.1 Psychosis: An Overview2.1.1 Psychosis2.1.2 Psychotic Disorder2.1.3 Schizophrenia2.1.4 Bipolar Disorder2.2 Antipsychotics: An Overview2.3 Tardive Dyskinesia: An Overview2.3.1 Signs and Symptoms2.3.2 Causes2.3.3 Treatment2.3.4 Existing and Pipeline Drugs3. US Market Analysis3.1 US Tardive Dyskinesia Market: An Analysis3.1.1 US Tardive Dyskinesia Market by Number of Patients3.1.2 US Tardive Dyskinesia Market Number of Patients by Segments3.1.3 US Tardive Dyskinesia Market Number of Patients by Severity3.2 US Tardive Dyskinesia Drugs Market; An Analysis3.2.1 US Valbenazine Market by Penetration3.2.2 US Valbenazine Market by Number of Patients3.2.3 US Valbenazine Market by Price and Revenue3.2.4 US SD-809 Market by Penetration3.2.5 US Tetrabenazine Market (For TD) by Penetration4. Market Dynamics4.1 Growth Drivers4.1.1 Increasing Schizophrenia Patients4.1.2  Rising Bipolar Disorder Patients4.1.3 Growing Antipsychotics Prescription4.2 Challenges4.2.1 Tardive Dyskinesia Prevalence by Drug Class4.2.2 Side Effects of Drugs4.2.3 Under-diagnosed4.3 Market Trends4.3.1 Medications Causing Tardive Dyskinesia4.3.2 Diagnosis of Tardive Dyskinesia5. Competitive Landscape6. Company Profiling

Browse All Latest Pharmaceuticals Market Research Reports at

About Us:MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Media Contact: Ritesh Tiwari, Market Reports Online, + 1 888 391 5441, [email protected]

News distributed by PR Newswire iReach:

SOURCE Market Reports Online

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store